Trinity Biotech PLC (TRIB) stock
TRIBNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$5.83−0.18 (-3.08%)
Close on Nov 18, 2026Market cap $108.99MP/E –Yield –
Trinity Biotech revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
For fiscal 2025 it was $43.79M, down 28.9% from the year before. Over ten years it grew -7.9% a year on average. The highest annual figure on record is $101.98M in fiscal 2020.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $43.79M | -28.9% |
| FY2024 | Dec 31, 2024 | $61.56M | +8.3% |
| FY2023 | Dec 31, 2023 | $56.83M | -9.1% |
| FY2022 | Dec 31, 2022 | $62.52M | -23.0% |
| FY2021 | Dec 31, 2021 | $81.15M | -20.4% |
| FY2020 | Dec 31, 2020 | $101.98M | +12.8% |
| FY2019 | Dec 31, 2019 | $90.44M | -6.8% |
| FY2018 | Dec 31, 2018 | $97.04M | -2.1% |
| FY2017 | Dec 31, 2017 | $99.14M | -0.5% |
| FY2016 | Dec 31, 2016 | $99.61M | -0.6% |
| FY2015 | Dec 31, 2015 | $100.20M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2018 | Jun 30, 2018 | $25.00M | – |
| Q2 FY2017 | Jun 30, 2017 | $25.45M | – |
See a number that looks wrong?